EDP 1632
Alternative Names: EDP-1632Latest Information Update: 28 Jan 2024
At a glance
- Originator Evelo Biosciences
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 26 Jan 2024 Discontinued - Preclinical for Inflammation in USA (PO)
- 13 Dec 2019 Evelo Biosciences has patent protection for its pipeline of monoclonal microbials, as well as for its platform technology (Evelo Biosciences website, December 2019)